Project Grant K08AI183990
Award Date
8/5/24
Completion Date
7/31/29
Dollars Obligated
$186K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $128,250 to the Fred Hutchinson Cancer Center in Seattle, WA to develop novel chimeric antigen receptor (CAR) T cell therapies targeting the PD-1 immune checkpoint protein. The goal is to create a more specific and safer second-generation anti-PD-1 CAR T cell therapy to deplete the HIV reservoir within T...
This Project Grant award, valued at $1,821,515.00 and effective July 22, 2024 through May 31, 2029, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this research is to develop and evaluate bi-specific chimeric antigen receptors (CARs) that can recognize both cytomegalovirus (CMV) and HIV-1 antigens. This approach aims to create cytotoxic T lymphocytes (CTLs) that can be...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $343,744 to support the development of a comprehensive strategy for an Investigational New Drug (IND) application and clinical implementation of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy approach to functionally cure HIV infection. The research plan involves three key...
This $107,948 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to engineer B cells for enhanced control of HIV. The key objectives are to: Design synthetic protein signaling molecules to engage B cell circuits induced by T helper cells and screen their function in cell-based models. Examine the ability of these signaling molecules to drive key B cell functions in...
This $2,688,880 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key research objectives include: Comprehensively testing the effects of IL-15/IL-15RA therapy combined with TGF-beta pathway blockade on different T and NK cell subsets during chronic SIV...
This $1,657,972 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to characterize allogeneic T cell responses that mediate a functional cure for HIV. The project will define the allogeneic T cell responses and their targets in individuals cured of HIV following allogeneic hematopoietic stem cell transplantation (alloSCT), as well as in a non-human primate model. The project will...
The University of California, Los Angeles (UCLA) has been awarded a $797,711 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this 2-year grant is to develop an in vivo T-cell therapy for HIV treatment using virus-like particles (VLPs) to deliver mRNA encoding T-cell receptors or chimeric antigen receptors directly to T cells in the patient's blood and lymph system. This...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to target CD127-expressing tissue reservoir cells as a strategy for HIV cure. The $250,791 award will fund research to leverage a chimeric CD127 monoclonal antibody called 4A10 to inhibit IL7-mediated signaling and deplete CD127-expressing HIV reservoir cells, with the goal of reducing the HIV reservoir...
This $194,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research to develop virus-like particles (VLPs) for a novel HIV-1 cure strategy. The project aims to use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent (the "shock") and then target the reactivated cells for elimination using adeno-associated virus (AAV) vectors expressing broadly...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel cure strategy for HIV-1 that combines small-molecule CD4-mimetic compounds (CD4MCs) with CD4-induced antibodies (CD4I Abs). The total funding amount is $1,314,572, awarded to Yale University with a period of performance from August 2024 to June 2029. The research project...